Owkin and Proscia have partnered to advance colorectal cancer diagnosis using AI. Owkin’s MSIntuit® CRC v2, an advanced diagnostic tool, will integrate with Proscia’s Concentriq® software platform, becoming part of its precision medicine AI portfolio. This collaboration aims to help pathologists efficiently pre-screen patients with microsatellite stable (MSS) or proficient mismatch repair (pMMR) colorectal tumors, addressing the growing demand for MSI screening. MSIntuit CRC v2 builds on the success of its CE-IVD-certified predecessor, offering sensitivity comparable to traditional testing while reducing unnecessary tests for nearly half of patients. By integrating this AI diagnostic into major pathology labs, the partnership seeks to expand access to more efficient and accurate testing. Owkin and Proscia share a vision to transform precision medicine through AI, combining their expertise to streamline diagnostic workflows and improve patient outcomes. Read the full article on Pathology News: https://lnkd.in/eDhxtfXY #digitalpathology #pathologynews
Thank you for sharing! We're looking forward to seeing the impact of our collaboration with Owkin.